Effects of obesity on vascular potassium channels

Current Vascular Pharmacology

Volumn 12, Issue 3, 2014, Pages 438-452

  Climent, Belen ^a   Simonsen, Ulf ^b   Rivera, Luis ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

Endothelium; Insulin resistance; KATP channels; KCa channels; KIR channels; KV channels; Metabolic syndrome; Obesity; Vascular smooth muscle cell

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; CALCIUM ACTIVATED POTASSIUM CHANNEL; CROMAKALIM; DIAZOXIDE; GLIBENCLAMIDE; INWARDLY RECTIFYING POTASSIUM CHANNEL; IPTAKALIM; LEMAKALIM; NICORANDIL; PINACIDIL; POTASSIUM CHANNEL; TANDEM PORE DOMAIN POTASSIUM CHANNEL; VOLTAGE GATED POTASSIUM CHANNEL;

ARTICLE; CARDIOVASCULAR RISK; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERLIPIDEMIA; HYPERPOLARIZATION; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; UPREGULATION; VASCULAR SMOOTH MUSCLE; VASODILATATION; VASOMOTOR REFLEX; ANIMAL; BLOOD VESSEL; DISEASE MODEL; GENETICS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

ANIMALS; BLOOD VESSELS; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; HUMANS; OBESITY; POTASSIUM CHANNELS; VASODILATION;

EID: 84907819466     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161112666140423221622     Document Type: Article

References (229)

1. [1] Grgic I, Kaistha BP, Hoyer J, et al. Endothelial Ca2+-activated K+ channels in normal and impaired EDHF-dilator responses-relevance to cardiovascular pathologies and drug discovery. Br J Pharmacol 2009; 157: 509-26.
2. [2] Quayle JM, Nelson MT, Standen NB. ATP-sensitive potassium channels and inwardly rectifying potassium channels in smooth muscle. Physiol Rev 1997; 77: 1165-232.
3. [3] Jepps TA, Olesen SP, Greenwood IA. One man’s side effect is another man's therapeutic opportunity: targeting Kv7 channels in smooth muscle disorders. Br J Pharmacol 2013; 168: 19-27.
4. [4] Nielsen G, Wandall-Frostholm C, Sadda V, et al. Alterations of N-3 polyunsaturated fatty acid-activated K2P channelsin hypoxiainduced pulmonary hypertension. Basic Clin Pharmacol Toxicol 2013: 113(4): 250-8.
5. [5] Félétou M, Köhler R, Vanhoutte PM. Endothelium-derived Vasoactive Factors and Hypertension: Possible Roles in Pathogenesis and as Treatment Targets. Curr Hypertens Rep 2010; 12: 267-75.
6. [6] Félétou M, Köhler R, Vanhoutte PM. Nitric oxide: orchestrator of endothelium-dependent responses. Ann Med 2012; 44: 694-716.
7. [7] Edwards G, Félétou M, Weston AH. Endothelium-derived hyperpolarising factors and associated pathways: a synopsis. Pflugers Arch 2010; 459: 863-79.
8. [8] Fleming I, Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol 2003; 284: R1-12.
9. [9] Nilius B, Droogmans G. Ion channels and their functional role in vascular endothelium. Physiol Rev 2001; 81: 1415-59.
10. [10] Fleming I, Busse R. Endothelium-derived epoxyeicosatrienoic acids and vascular function. Hypertension 2006; 47: 629-33.
11. [11] Nelson M, Huang Y, Brayden J, et al. Arterial dilations in response to calcitonin gene-related peptide involve activation of K+ channels. Nature 1990; 344: 770-3.
12. [12] Bolton TB, Gordienko D V, Pucovsky V. Calcium release events in excitation contraction coupling in smooth muscle. Novartis Found Symp 2002; 242: 154-68.
13. [13] Del Valle-Rodriguez A, Lopez-Barneo J, Urena J. Ca2+ channelsarcoplasmic reticulum coupling: a mechanism of arterial myocyte contraction without Ca2+ influx. EMBO J 2003; 22: 4337-45.
14. [14] Schachinger V, Britten MB, Zeiher AM. Prognostic Impact of Coronary Vasodilator Dysfunction on Adverse Long-Term Outcome of Coronary Heart Disease. Circulation 2000; 101: 1899-906.
15. [15] Neunteufl T, Heher S, Katzenschlager R, et al. Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. Am J Cardiol 2000; 86: 207-10.
16. [16] Nitenberg A, Valensi P, Sachs R, et al. Prognostic value of epicardial coronary artery constriction to the cold pressor test in type 2 diabetic patients with angiographically normal coronary arteries and no other major coronary risk factors. Diabetes Care 2004; 27: 208-15.
17. [17] Nitenberg A, Pham I, Antony I, et al. Cardiovascular outcome of patients with abnormal coronary vasomotion and normal coronary arteriography is worse in type 2 diabetes mellitus than in arterial hypertension: a 10 year follow-up study. Atherosclerosis 2005; 183: 113-20.
18. [18] Perticone F, Ceravolo R, Pujia A, et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001; 104: 191-6.
19. [19] Frisbee JC, Maier KG, Stepp DW. Oxidant stress-induced increase in myogenic activation of skeletal muscle resistance arteries in obese Zucker rats. Am J Physiol Heart Circul Physiol 2002; 283: H2160-8.
20. [20] Naderali EK, Pickavance LC, Wilding JPH, et al. Diet-induced endothelial dysfunction in the rat is independent of the degree of increase in total body weight. Clin Sci 2001; 100: 635-641.
21. [21] Erdös B, Miller AW, Busija DW. Alterations in KATP and KCa channel function in cerebral arteries of insulin-resistant rats. Am J Physiol Heart Circul Physiol 2002; 283: H2472-H24777.
22. [22] Bagi Z, Feher A, Cassuto J. Microvascular responsiveness in obesity: implications for therapeutic intervention. Br J Pharmacol 2012; 165: 544-60.
23. [23] Vanhoutte PM, Shimokawa H, Tan EHC, et al. Endothelial dysfunction and vascular disease. Acta Physiol 2009; 196: 193-222.
24. [24] Erdös B, Simandle SA, Snipes JA, et al. Potassium channel dysfunction in cerebral arteries of insulin-resistant rats is mediated by reactive oxygen species. Stroke 2004; 35: 96496-9.
25. [25] Ruderman NB, Williamson J, Brownlee M. Glucose and diabetic vascular disease. FASEB J 1992; 6: 2905-14.
26. [26] Bohlen H, Lash J. Topical hyperglycemia rapidly suppresses EDRF-mediated vasodilation of normal rat arterioles. Am J Physiol Heart Circul Physiol 1993; 265: H219-25.
27. [27] Bagi Z, Koller A. Lack of nitric oxide mediation of flow-dependent arteriolar dilation in type I diabetes is restored by sepiapterin. J Vasc Res 2003; 40: 47-57.
28. [28] Erdös B, Snipes JA, Miller AW, et al. Cerebrovascular dysfunction in Zucker obese rats is mediated by oxidative stress and protein kinase C. Diabetes 2004; 53: 1352-9.
29. [29] Félétou M. Calcium-activated potassium channels and endothelial dysfunction: therapeutic options? Br J Pharmacol 2009; 156: 545-62.
30. [30] Köhler R, Kaistha B, Wulff H. Vascular KCa-channels as therapeutic targets in hypertension and restenosis disease. Exp Opin Ther Targets 2010; 14: 143-55.
31. [31] Dalsgaard T, Kroigaard C, Simonsen U. Calcium-activated potassium channels-a therapeutic target for modulating nitric oxide in cardiovascular disease? Expert Opin Ther Targets 2010; 14: 825-37.
32. [32] Hibino H, Inanobe A, Furutani K, et al. Inwardly Rectifying Potassium Channels: Their Structure, Function, and Physiological Roles. Physiol Rev 2010; 90: 291-366.
33. [33] Park WS, Han J, Earm YE. Physiological role of inward rectifier K(+) channels in vascular smooth muscle cells. Pflugers Arch 2008; 457: 137-47.
34. [34] Wulff H, Zhorov BS. K+ channel modulators for the treatment of neurological disorders and autoimmune diseases. Chem Rev 2008; 108: 1744-73.
35. [35] Wulff H, Köhler R. Endothelial small-conductance and intermediate-conductance KCa channels: an update on their pharmacology and usefulness as cardiovascular targets. J Cardiovasc Pharmacol 2013; 61: 102-12.
36. [36] Wei A, Gutman G, Aldrich R, et al. International Union of Pharmacology. LII. Nomenclature and Molecular Relationships of Calcium-Activated Potassium Channels. J Pharmacol Exp Ther 2005; 57: 463-72.
37. [37] Neylon CB, Lang RJ, Fu Y, et al. Molecular Cloning and Characterization of the Intermediate-Conductance Ca2+-Activated K+ Channel in Vascular Smooth Muscle: Relationship Between KCa Channel Diversity and Smooth Muscle Cell Function. Circ Res 1999; 85: e33-e43.
38. [38] Fanger CM, Ghanshani S, Logsdon NJ, et al. Calmodulin mediates calcium-dependent activation of the intermediate conductance KCa channel, IKCa1. J Biol Chem 1999; 274: 5746-54.
39. [39] Ishii T, Silvia C, Hirschberg B, et al. A human intermediate conductance calcium-activated. Proc Natl Acad Sci USA 1997; 94: 11651-6.
40. [40] Wulff H, Kolski-Andreaco A, Sankaranarayanan A, et al. Modulators of small-and intermediate-conductance calcium-activated potassium channels and their therapeutic indications. Curr Med Chem 2007; 14: 1437-57.
41. [41] Marchenko SM, Sage SO. Calcium-activated potassium channels in the endothelium of intact rat aorta. J Physiol 1996; 492: 53-60.
42. [42] Burnham MP, Bychkov R, Félétou M, et al. Characterization of an apamin-sensitive small-conductance Ca(2+)-activated K(+) channel in porcine coronary artery endothelium: relevance to EDHF. Br J Pharmacol 2002; 135: 1133-43.
43. [43] Köhler R, Hoyer J. The endothelium-derived hyperpolarizing factor: insights from genetic animal models. Kidney Intl 2007; 72: 145-50.
44. [44] Dalsgaard T, Kroigaard C, Simonsen U. Calcium-activated potassium channels-a therapeutic target for modulating nitric oxide in cardiovascular disease? Expert Opin Ther Targets 2010; 14: 825-37.
45. [45] Dora K, Gallagher NT, McNeish A, et al. Modulation of endothelial cell KCa3.1 channels during endothelium-derived hyperpolarizing factor signaling in mesenteric resistance arteries. Circ Res 2008; 102: 1247-55.
46. [46] Sandow SL, Neylon CB, Chen MX, et al. Spatial separation of endothelial small-and intermediate-conductance calcium-activated potassium channels (K(Ca)) and connexins: possible relationship to vasodilator function? J Anat 2006; 209: 689-98.
47. [47] Remillard CV, Yuan JX. Transient Receptor Potential Channels and Caveolin-1: Good Friends in Tight Spaces. Mol Pharmacol 2006; 70: 1151-4.
48. [48] Saliez J, Bouzin C, Rath G, et al. Role of caveolar compartmentation in endothelium-derived hyperpolarizing factor-mediated relaxation: Ca2+ signals and gap junction function are regulated by caveolin in endothelial cells. Circulation 2008; 117: 1065-74.
49. [49] Köhler R, Wulff H, Eichler I, et al. Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis. Circulation 2003; 108: 1119-25.
50. [50] Gebremedhin D, Kaldunski M, Jacobs E, et al. Coexistence of two types of Ca(2+)-activated K+ channels in rat renal arterioles. Am J Physiol 1996; 270: F69-81.
51. [51] Quignard JF, Félétou M, Edwards G, et al. Role of endothelial cell hyperpolarization in EDHF-mediated responses in the guinea-pig carotid artery. Br J Pharmacol 2000; 129: 1103-12.
52. [52] Sultan S, Gosling M, Abu-Hayyeh S, et al. Flow-dependent increase of ICAM-1 on saphenous vein endothelium is sensitive to apamin. Am J Physiol Heart Circul Physiol 2004; 287: H22-8.
53. [53] Simonsen U, García-Sacristán A, Prieto D. Apamin-sensitive K+ channels involved in the inhibition of acetylcholine-induced contractions in lamb coronary small arteries. Eur J Pharmacol 1997; 329: 153-63.
54. [54] Garland C, Hiley C, Dora K. EDHF: spreading the influence of the endothelium. Br J Pharmacol 2011; 164: 839-52.
55. [55] Busse R, Fichtner H, Lückhoff A, et al. Hyperpolarization and increased free calcium in acetylcholine-stimulated endothelial cells. Am J Physiol Heart Circul Physiol 1988; 255: H965-969.
56. [56] Lückhoff A, Busse R. Activators of potassium channels enhance calcium influx into endothelial cells as a consequence of potassium currents. Naunyn Schmiedebergs Arch Pharmacol 1990; 342: 94-9.
57. [57] Stankevicius E, Lopez-Valverde V, Rivera L, et al. Combination of Ca2+-activated K+ channel blockers inhibits acetylcholine-evoked nitric oxide release in rat superior mesenteric artery. Br J Pharmacol 2006; 149: 560-72.
58. [58] Sheng J-Z, Braun AP. Small-and intermediate-conductance Ca2+-activated K+ channels directly control agonist-evoked nitric oxide synthesis in human vascular endothelial cells. Am J Physiol Cell Physiol 2007; 293: C458-67.
59. [59] Dalsgaard T, Kroigaard C, Bek T, Simonsen U. Role of calcium-activated potassium channels with small conductance in bradykinin-induced vasodilation of porcine retinal arterioles. Inves Ophthalmol Vis Sci 2009; 50: 3819-25.
60. [60] Climent B, Schubert R, Stankevicius E, et al. Large conductance Ca2+-activated K+ channels modulate endothelial cell outward currents and nitric oxide release in the intact rat superior mesenteric artery. Biochem Biophys Res Commun 2012; 417: 1007-13.
61. [61] Gao X, Martinez-Lemus LA, Zhang C. Endothelium-derived hyperpolarizing factor and diabetes. World J Cardiol 2011; 3: 25-31.
62. [62] Stapleton PA, James ME, Goodwill AG, et al. Obesity and vascular dysfunction. Pathophysiology 2008; 15: 79-89.
63. [63] Bond C, Maylie J, Adelman JP. SK channels in excitability, pacemaking and synaptic integration. Curr Opin Neurobiol 2005; 15: 305-11.
64. [64] Liégeois J, Mercier F, Graulich A, et al. Modulation of small conductance calcium-activated potassium (SK) channels: a new challenge in medicinal chemistry. Curr Med Chem 2003; 10: 625-47.
65. [65] Peña T, Chen S, Konieczny S, et al. Ras/MEK/ERK Up-regulation of the fibroblast KCa channel FIK is a common mechanism for basic fibroblast growth factor and transforming growth factor-beta suppression of myogenesis. J Biol Chem 2000; 275: 13677-82.
66. [66] Ghanshani S, Wulff H, Miller MJ, et al. Up-regulation of the IKCa1 Potassium Channel during T-cell Activation. J Biol Chem 2013; 275: 37137-49.
67. [67] Potier M, Joulin V, Roger S, et al. Identification of SK3 channel as a new mediator of breast cancer cell migration. Mol Cancer Ther 2006; 5: 2946-53.
68. [68] Kasumu AW, Hougaard C, Rode F, et al. Selective positive modulator of calcium-activated potassium channels exerts beneficial effects in a mouse model of spinocerebellar ataxia type 2. Chem Biol 2012; 19: 1340-53.
69. [69] Wölfle SE, De Wit C. Intact endothelium-dependent dilation and conducted responses in resistance vessels of hypercholesterolemic mice in vivo. J Vasc Res 2005; 42: 475-82.
70. [70] Ellis A, Cheng Z-J, Yang L, et al. Effects of a Western diet versus high glucose on endothelium-dependent relaxation in murine micro-and macro-vasculature. Eur J Pharmacol 2008; 601: 111-7.
71. [71] Chadha PS, Haddock RE, Howitt L, et al. Obesity up-regulates intermediate conductance calcium-activated potassium channels and myoendothelial gap junctions to maintain endothelial vasodilator function. J Pharmacol Exp Ther 2010; 335: 284-93.
72. [72] Haddock RE, Grayson TH, Morris MJ, et al. Diet-induced obesity impairs endothelium-derived hyperpolarization via altered potassium channel signaling mechanisms. PloS One 2011; 6: e16423.
73. [73] Young EJ, Hill MA, Wiehler WB, et al. Reduced EDHF responses and connexin activity in mesenteric arteries from the insulin-resistant obese Zucker rat. Diabetologia 2008; 51: 872-81.
74. [74] Miller AW, Hoenig ME, Ujhelyi MR. Mechanisms of Impaired Endothelial Function Associated with Insulin Resistance. J Cardiovasc Pharmacol Ther 1998; 3: 125-33.
75. [75] Miller AW, Katakam P, Ujhelyi MR. Impaired endothelium-mediated relaxation in coronary arteries from insulin-resistant rats. J Vasc Res 1999; 36: 385-92.
76. [76] Erdös B, Snipes JA, Tulbert CD, et al. Rosuvastatin improves cerebrovascular function in Zucker obese rats by inhibiting NAD(P)H oxidase-dependent superoxide production. Am J Physiol Heart Circul Physiol 2006; 290: H1264-70.
77. [77] Agouni A, Lagrue-Lak-Hal A-H, Mostefai HA, et al. Red wine polyphenols prevent metabolic and cardiovascular alterations associated with obesity in Zucker fatty rats (Fa/Fa). PloS One 2009; 4: e5557.
78. [78] Caballero A. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes Res 2003; 11: 1278-89.
79. [79] Galili O, Versari D, Sattler KJK, et al. Early experimental obesity is associated with coronary endothelial dysfunction and oxidative stress. Am J Physiol Heart Circul Physiol 2007; 292: H904-H911.
80. [80] Villalba N, Martínez P, Bríones AM, et al. Differential structural and functional changes in penile and coronary arteries from obese Zucker rats. Am J Physiol Heart Circul Physiol 2009; 297: H696-707.
81. [81] Ledoux J, Werner ME, Brayden JE, et al. Calcium-activated potassium channels and the regulation of vascular tone. Physiology 2006; 21: 69-78.
82. [82] Berkefeld H, Fakler B, Schulte U. Ca 2+-Activated K+ Channels: From Protein Complexes to Function. Physiol Rev 2010; 90: 1437-59.
83. [83] Knaus H, Eberhart A, Glossmann H, et al. Pharmacology and structure of high conductance calcium-activated potassium channels. Cell Signal 1994; 6: 861-70.
84. [84] Shieh CC, Coghlan M, Sullivan JP, et al. Potassium channels: molecular defects, diseases, and therapeutic opportunities. Pharmacol Rev 2000; 52: 557-94.
85. [85] Sandow SL, Grayson TH. Limits of isolation and culture: intact vascular endothelium and BKCa. Am J Physiol Heart Circul Physiol 2009; 297: H1-7.
86. [86] Baron A, Frieden M, Bény J. Epoxyeicosatrienoic acids activate a high-conductance, Ca(2+)-dependent K + channel on pig coronary artery endothelial cells. J Physiol 1997; 504: 537-43.
87. [87] Brakemeier S, Eichler I, Knorr A, et al. Modulation of Ca 2+-activated K+ channel in renal artery endothelium in situ by nitric oxide and reactive oxygen species. Kidney Int 2003; 64: 199-207.
88. [88] Hughes JM, Riddle MA, Paffett ML, et al. Novel role of endothelial BKCa channels in altered vasoreactivity following hypoxia. Am J Physiol Heart Circul Physiol 2010; 299: H1439-50.
89. [89] Köhler R, Brakemeier S, Kühn M, et al. Expression of ryanodine receptor type 3 and TRP channels in endothelial cells: comparison of in situ and cultured human endothelial cells. Cardiovasc Res 2001; 51: 160-8.
90. [90] Pérez GJ, Bonev AD, Patlak JB, et al. Functional coupling of ryanodine receptors to KCa channels in smooth muscle cells from rat cerebral arteries. J Gen Physiol 1999; 113: 229-38.
91. [91] Nelson MT, Quayle JM. Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol Cell Physiol 1995; 268: C799-822.
92. [92] Bolotina VM, Najibi S, Palacino JJ, et al. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature 1994; 368: 850-3.
93. [93] Archer SL, Huang JM, Hampl V, et al. Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase. Proc Natl Acad Sci USA 1994; 91: 7583-7.
94. [94] Alonso-Galicia M, Drummond HA, Reddy KK, et al. Inhibition of 20-HETE Production Contributes to the Vascular Responses to Nitric Oxide. Hypertension 1997; 29: 320-5.
95. [95] Schubert R, Nelson MT. Protein kinases: tuners of the BKCa channel in smooth muscle. Trends Pharmacol Sci 2001; 22: 505-12.
96. [96] Gutterman DD, Miura H, Liu Y. Redox modulation of vascular tone: focus of potassium channel mechanisms of dilation. Arterioscler Thromb Vasc Biol 2005; 25: 671-8.
97. [97] Wang ZW, Nara M, Wang YX, et al. Redox regulation of large conductance Ca(2+)-activated K+ channels in smooth muscle cells. J Gen Physiol 1997; 110: 35-44.
98. [98] Liu Y, Terata K, Chai Q, et al. Peroxynitrite Inhibits Ca2+-Activated K+ Channel Activity in Smooth Muscle of Human Coronary Arterioles. Circ Res 2002; 91: 1070-6.
99. [99] Zhang DX, Zou AP, Li PL. Ceramide-induced activation of NADPH oxidase and endothelial dysfunction in small coronary arteries. Am J Physiol Heart Circul Physiol 2003; 284: H605-12.
100. [100] Bychkov R, Pieper K, Ried C, et al. Hydrogen Peroxide, Potassium Currents, and Membrane Potential in Human Endothelial Cells. Circulation 1999; 99: 1719-25.
101. [101] Sobey CG, Heistad DD, Faraci FM. Mechanisms of Bradykinin-Induced Cerebral Vasodilatation in Rats: Evidence That Reactive Oxygen Species Activate K+ Channels. Stroke 1997; 28: 2290-5.
102. [102] Tang XD, Garcia ML, Heinemann SH, et al. Reactive oxygen species impair Slo1 BK channel function by altering cysteine-mediated calcium sensing. Nat Struct Mol Biol 2004; 11: 171-8.
103. [103] Brzezinska AK, Gebremedhin D, Chilian WM, et al. Peroxynitrite reversibly inhibits Ca2+-activated K+ channels in rat cerebral artery smooth muscle cells. Am J Physiol Heart Circ Physiol 2000; 278: H1883-H1890.
104. [104] Valverde MA, Rojas P, Amigo J, et al. Acute activation of Maxi-K channels (hSlo) by estradiol binding to the beta subunit. Science 1999; 285: 1929-31.
105. [105] Chambliss KL, Wu Q, Oltmann S, et al. Non-nuclear estrogen receptor alpha signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. J Clin Invest 2010; 120: 2319-30.
106. [106] Novella S, Dantas AP, Segarra G, et al. Vascular Aging in Women: is Estrogen the Fountain of Youth? Front Physiol 2012; 3: 165.
107. [107] Mauvais-Jarvis F, Clegg DJ, Hevener AL. The Role of Estrogens in Control of Energy Balance and Glucose Homeostasis. Endocr Rev 2013; 34: 309-38.
108. [108] Gollasch M. Vasodilator signals from perivascular adipose tissue. Br J Pharmacol 2012; 165: 633-42.
109. [109] Aghamohammadzadeh R, Withers S, Lynch F, et al. Perivascular adipose tissue from human systemic and coronary vessels: the emergence of a new pharmacotherapeutic target. Br J Pharmacol 2012; 165: 670-82.
110. [110] Fésüs G, Dubrovska G, Gorzelniak K, et al. Adiponectin is a novel humoral vasodilator. Cardiovasc Res 2007; 75: 719-27.
111. [111] Lynch F, Withers S, Yao Z, et al. Perivascular adipose tissue-derived adiponectin activates BKCa channels to induce anticontractile responses. Am J Physiol Heart Circ Physiol 2013; 304: H786-95.
112. [112] Sanchez M, McManus OB. Paxilline inhibition of the alpha-subunit of the high-conductance calcium-activated potassium channel. Neuropharmacology 1996; 35: 963-8.
113. [113] Gribkoff V, Starrett J, Dworetzky S. Maxi-K potassium channels: form, function, and modulation of a class of endogenous regulators of intracellular calcium. Neuroscientist 2001; 7: 166-77.
114. [114] Bentzen BH, Nardi A, Calloe K, et al. The Small Molecule NS11021 Is a Potent and Specific Activator of Ca 2+-Activated Big-Conductance K + Channels. J Pharmacol Exp Ther 2007; 72: 1033-44.
115. [115] Nardi A, Olesen S. BK channel modulators: a comprehensive overview. Curr Med Chem 2008; 15: 1126-46.
116. [116] Jensen BS. BMS-204352: a potassium channel opener developed for the treatment of stroke. CNS Drug Rev 2002; 8: 353-60.
117. [117] Borbouse L, Dick GM, Asano S, et al. Impaired function of coronary BK(Ca) channels in metabolic syndrome. Am J Physiol Heart Circ Physiol 2009; 297: H1629-H1637.
118. [118] Borbouse L, Dick GM, Payne GA, et al. Metabolic syndrome reduces the contribution of K+ channels to ischemic coronary vasodilation. Am J Physiol Heart Circ Physiol 2010; 298: H1182-H1189.
119. [119] Howitt L, Sandow SL, Grayson TH, et al. Differential effects of diet-induced obesity on BKCa {beta}1-subunit expression and function in rat skeletal muscle arterioles and small cerebral arteries. Am J Physiol Heart Circ Physiol 2011; 301: H29-40.
120. [120] Shangjian L, Deng Z, Wei L, et al. Reduction of large-conductance Ca2+-activated K+ channel with compensatory increase of nitric oxide in insulin resistant rats. Diabetes Met Res Rev 2011; 27: 461-9.
121. [121] Howitt L, Grayson TH, Morris MJ, et al. Dietary obesity increases NO and inhibits BKCa-mediated, endothelium-dependent dilation in rat cremaster muscle artery: association with caveolins and caveolae. Am J Physiol Heart Circ Physiol 2012; 302: H2464-76.
122. [122] Amberg GC, Santana LF. Downregulation of the BK channel beta1 subunit in genetic hypertension. Circ Res 2003; 93: 965-71.
123. [123] McGahon MK, Dash DP, Arora A, et al. Diabetes downregulates large-conductance Ca2+-activated potassium beta 1 channel subunit in retinal arteriolar smooth muscle. Circ Res 2007; 100: 703-11.
124. [124] Wang Y, Zhang H, Su X, et al. Experimental diabetes mellitus down-regulates large-conductance Ca2+-activated K+ channels in cerebral artery smooth muscle and alters functional conductance. Curr Neurovasc Res 2010; 7: 75-84.
125. [125] Xia X, Hirschberg B, Smolik S. dSLo Interacting Protein 1, a Novel Protein That Interacts with Large-Conductance Calcium-Activated Potassium Channels. J Pharmacol Exp Ther 1998; 18: 2360-9.
126. [126] Xie J, Jan C, Stoilov P, et al. A consensus CaMK IV-responsive RNA sequence mediates regulation of alternative exons in neurons. RNA 2005; 11: 1825-34.
127. [127] Belin de Chantemele EJ, Stepp DW. Influence of obesity and metabolic dysfunction on the endothelial control in the coronary circulation. J Mol Cell Cardiol 2012; 52: 840-7.
128. [128] Feher A, Rutkai I, Beleznai T, et al. Caveolin-1 limits the contribution of BK(Ca) channel to EDHF-mediated arteriolar dilation: implications in diet-induced obesity. Cardiovasc Res 2010; 87: 732-9.
129. [129] Li P, Shibata R, Unno K, et al. Evidence for the importance of adiponectin in the cardioprotective effects of pioglitazone. Hypertension 2010; 55: 69-75.
130. [130] Gollasch M, Dubrovska G. Paracrine role for periadventitial adipose tissue in the regulation of arterial tone. Trends Pharmacol Sci 2004; 25: 647-53.
131. [131] Köhler R. Single-nucleotide polymorphisms in vascular Ca2+-activated K+-channel genes and cardiovascular disease. Pflugers Arch 2010; 460: 343-51.
132. [132] Yamaguchi M, Nakayama T, Fu Z, et al. Relationship between haplotypes of KCNN4 gene and susceptibility to human vascular diseases in Japanese. Med Sci Monit 2009; 15: CR389-CR397.
133. [133] Tomás M, Vázquez E, Fernández-Fernández JM, et al. Genetic variation in the KCNMA1 potassium channel alpha subunit as risk factor for severe essential hypertension and myocardial infarction. J Hypertens 2008; 26: 2147-53.
134. [134] Nilius B, Viana F, Droogmans G. Ion channels in vascular endothelium. Ann Rev Physiol 1997; 59: 145-70.
135. [135] Nelson M, Quayle J. Physiological roles and properties of potassium channels in arterial smooth muscle. A J Physiol Cell Physiol 1995; 268: C799-C822.
136. [136] Janigro D, West G, Gordon E, et al. ATP-sensitive K+ channels in rat aorta and brain microvascular endothelial cells. Am J Physiol Cell Physiol 1993; 265: C812-C821.
137. [137] Mederos y Schnitzler M, Derst C, Daut J, et al. ATP-sensitive potassium channels in capillaries isolated from guinea-pig heart. J Physiol 2000; 525: 307-17.
138. [138] Lopatin A, Makhina E, Nichols C. Potassium channel block by cytoplasmic polyamines as the mechanism of intrinsic rectification. Nature 1994; 372: 366-9.
139. [139] Lopatin A, Makhina E, Nichols C. The mechanism of inward rectification of potassium channels: “long-pore plugging” by cytoplasmic polyamines. J Gen Physiol 1995; 106: 923-55.
140. [140] Lu Z. Mechanisms of rectification in inward rectifier K+ channels. Annu Rev Physiol 2004; 66: 103-29.
141. [141] Kubo Y, Baldwin T, Jan Y, et al. Primary structure and functional expression of a mouse inward rectifier potassium channel. Nature 1993; 362: 127-33.
142. [142] Takahashi N, Morishige K, Jahangir A, et al. Molecular cloning and functional expression of cDNA encoding a second class of inward rectifier potassium channel. J Biol Chem 1994; 269: 23274-23279.
143. [143] Preisig-Müller R. Heteromerization of Kir2.x potassium channels contributes to the phenotype of Andersen’s syndrome. Proc Natl Acad Sci USA 2002; 99: 7774-9.
144. [144] Kubo Y, Adelman J, Clapham D, et al. International Union of Pharmacology. LIV. Nomenclature and Molecular Relationships of Inwardly Rectifying Potassium Channels. Pharmacol Rev 2005; 57: 509-26.
145. [145] Son Y, Park W, Ko J, et al. Protein kinase A-dependent activation of inward rectifier potassium channels by adenosine in rabbit coronary smooth muscle cells. Biochem Biophys Res Commun 2005; 337: 1145-52.
146. [146] Climent B, Zsiros E, Stankevicius E, et al. Intact rat superior mesenteric artery endothelium is an electrical syncytium and expresses strong inward rectifier K+ conductance. Biochem Biophys Res Commun 2011; 410: 501-7.
147. [147] Park WS, Ko J-H, Kim N, et al. Increased inhibition of inward rectifier K+ channels by angiotensin II in small-diameter coronary artery of isoproterenol-induced hypertrophied model. Arterioscler Thromb Vasc Biol 2007; 27: 1768-75.
148. [148] Chrissobolis S, Ziogas J, Chu Y, et al. Role of inwardly rectifying K(+) channels in K(+)-induced cerebral vasodilatation in vivo. Am J Physiol Heart Circul Physiol 2000; 279: H2704-12.
149. [149] Hogg DS, McMurray G, Kozlowski RZ. Endothelial cells freshly isolated from small pulmonary arteries of the rat possess multiple distinct K+ current profiles. Lung 2002; 180: 203-14.
150. [150] Eschke D, Richter M, Brylla E, et al. Identification ofinwardly rectifying potassium channels in bovine retinal and choroidal endothelial cells. Ophthalmic Res 2002; 34: 343-8.
151. [151] Crane GJ, Walker SD, Dora KA, et al. Evidence for a differential cellulardistribution of inward rectifier K channels in the rat isolated mesenteric artery. J Vasc Res 2003; 40: 159-68.
152. [152] Millar ID, Wang S, Brown PD, et al. Kv1 and Kir2 potassium channels are expressed in rat brain endothelial cells. Pflugers Arch Eur J Physiol 2008; 456: 379-91.
153. [153] Fang Y, Schram G, Romanenko VG, et al. Functional expression of Kir2.x in human aortic endothelial cells: the dominant role of Kir2.2. Am J Physiol Cell Physiol 2005; 289: C1134-C1144.
154. [154] Cao C, Lee-kwon W, Payne K, et al. Descending vasa recta endothelia express inward rectifier potassium channels. Am J Physiol Renal Physiol 2007; 293: 1248-55.
155. [155] Olesen S, Clapham D, Davies P. Haemodynamic shear stress activates a K+ current in vascular endothelial cells. Nature 1988; 331: 168-70.
156. [156] Quayle JM, Dart C, Standen NB. The properties and distribution of inward rectifier potassium currents in pig coronary arterial smooth muscle. J Physiol 1996; 494: 715-26.
157. [157] Chilton L, Smirnov SV, Loutzenhiser K, et al. Segment-specific differences in the inward rectifier K(+) current along the renal interlobular artery. Cardiovasc Res 2011; 92: 169-77.
158. [158] Chilton L, Loutzenhiser R. Functional evidence for an inward rectifier potassium current in rat renalafferent arterioles. Circ Res 2001; 88: 152-8.
159. [159] Eckman DM, Nelson MT. Potassium ions as vasodilators role of inward rectifier potassium channels. Circ Res 2001; 88: 132-3.
160. [160] Zaritsky J, Eckman D, Wellman G, et al. Targeted disruption of Kir2.1 and Kir2.2 genes reveals the essential role of the inwardly rectifying K(+) current in K(+)-mediated vasodilation. Circ Res 2000; 87: 160-6.
161. [161] Chilton L, Loutzenhiser K, Morales E, et al. Inward rectifier K(+) currents and Kir2.1 expression in renal afferent and efferent arterioles. J Am Soc Nephrol 2008; 19: 69-76.
162. [162] Tajada S, Cidad P, Moreno-Domínguez A, et al. High blood pressure associates with the remodelling of inward rectifier K+ channels in mice mesenteric vascular smooth muscle cells. J Physiol 2012; 590: 6075-91.
163. [163] Aguilar-Bryan L, Nichols CG, Wechsler SW, et al. Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science 1995; 268: 423-6.
164. [164] Ashcroft F, Gribble F. Correlating structure and function in ATP-sensitive K+ channels. Trends Neurosci 1998; 21: 288-94.
165. [165] Aguilar-Bryan L, Bryan J. Molecular biology of adenosine triphosphate-sensitive potassium channe. Endocr Rev 1999; 20: 101-35.
166. [166] Isomoto S, Kondo C, Yamada M, et al. A novel sulfonylurea receptor forms with BIR (Kir6.2) a smooth muscle type ATP-sensitive K+ channel. J Biol Chem 1996; 40: 24321-4.
167. [167] Yamada M, Isomoto S, Matsumoto S, et al. Sulfonyilurea receptor 2B and Kir6.1 form a sulfonylurea-sensitive but ATP-insensitive K + channel. J Physiol 1997; 499: 715-20.
168. [168] Inagaki N, Gonoi T, Clement JP, et al. Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor. Science 1995; 270: 1166-70.
169. [169] Beech D., Zhang H, Nakao K, et al. Single channel and whole-cell K-currents evoked by levcromakalim in smooth muscle cells from the rabbit portal vein. Br J Pharmacol 1993; 110: 583-90.
170. [170] Ruiz Rubio JL, Hernández M, Rivera de los Arcos L, et al. Role of ATP-sensitive K+ channels in relaxation of penile resistance arteries. Urology 2004; 63: 800-5.
171. [171] Sánchez A, Villalba N, Martínez AC, et al. Mechanisms of the relaxant effect of vardenafil in rat penile arteries. Eur J Pharmacol 2008; 586: 283-7.
172. [172] Misaki N, Mao X, Lin Y, et al. Iptakalim, a vascular ATP-sensitive potassium (KATP) channel opener, closes rat pancreatic b-cell KATP channels and increases insulin release. J Pharmacol Exp Ther 2007; 322: 871-8.
173. [173] Pan Z, Huang J, Cui W, et al. Targeting hypertension with a new adenosine triphosphate-sensitive potassium channel opener iptakalim. J Cardiovasc Pharmacol 2010; 56: 215-28.
174. [174] Wang Y, Zeng F, Long C, et al. The novel ATP-sensitive potassium channel opener iptakalim prevents insulin resistance associated with hypertension via restoring endothelial function. Acta Pharmacol Sin 2011; 32: 1466-74.
175. [175] Yang Y, Shi W, Cui N, et al. Oxidative stress inhibits vascular K(ATP) channels by S-glutathionylation. J Biol Chem 2010; 285: 38641-8.
176. [176] Miura H, Bosnjak J., Ning G, et al. Role for hydrogen peroxide in flow-induced dilation of human coronary arterioles. Circ Res 2003; 92: 31-40.
177. [177] Liu Y, Gutterman DD. Oxidative stress and potassium channel function. Clin Exp Pharmacol Physiol 2002; 29: 305-11.
178. [178] Kinoshita H, Matsuda N, Kaba H, et al. Roles of phosphatidylinositol 3-kinase-Akt and NADPH oxidase in adenosine 5’-triphosphate-sensitive K+ channel function impaired by high glucose in the human artery. Hypertension 2008; 52: 507-13.
179. [179] Liu Y. A new antihypertensive drug ameliorate insulin resistance. Acta Pharmacol Sin 2012; 33: 429-30.
180. [180] Potenza M, Marasciulo F, Chieppa D, et al. Insulin resistance in spontaneously hypertensiverats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production. Am J Physiol Heart Circ Physiol 2005; 289: H813-H822.
181. [181] Wang H, Long C, Duan Z, et al. A new ATP-sensitive potassium channel opener protects endothelial function in cultured aortic endothelial cells. Cardiovasc Res 2007; 73: 497-503.
182. [182] Lehrke M, Becker A, Greif M, et al. Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocr 2009; 161: 339-44.
183. [183] Zhao R, Wang H. Chemerin/ChemR23 signaling axis is involved in the endothelial protection by K(ATP) channel opener iptakalim. Acta Pharmacol Sin 2011; 32: 573-80.
184. [184] Fan LH, Tian HY, Wang J, et al. Downregulation of Kir6.1/SUR2B channels in the obese rat aorta. Nutrition 2009; 25: 359-63.
185. [185] Fan LH, Tian HY, Yang ML, et al. High-fat diet may impair K(ATP) channels in vascular smooth muscle cells. Biomed Pharmacother 2009; 63: 165-70.
186. [186] Hodnett BL, Xiang L, Dearman JA, et al. K(ATP)-mediated vasodilation is impaired in obese Zucker rats. Microcirculation 2008; 15: 485-94.
187. [187] Larsson O, Kindmark H, Bränström R, et al. Oscillations in KATP channel activity promote oscillations in cytoplasmic free Ca2+ concentration in the pancreatic b cell. Proc Natl Acad Sci USA 1996; 93: 5161-5.
188. [188] Bränström R, Corkey B, Berggren P, et al. Evidence for a unique long chain acyl-CoA ester binding site on the ATP-regulated potassium channel in mouse pancreatic beta cells. J Biol Chem 1997; 272: 17390-4.
189. [189] Bränström R, Aspinwall CA, Välimäki S, et al. Long-chain CoA esters activate human pancreatic beta-cell KATP channels: potential role in Type 2 diabetes. Diabetologia 2004; 47: 277-83.
190. [190] Gribble F, Proks P, Corkey B, et al. Mechanism of cloned ATP-sensitive potassium channel activation by oleoyl-CoA. J Biol Chem 1998; 273: 26383-7.
191. [191] Schulze D, Rapedius M, Krauter T, et al. Long-chain acyl-CoA esters and phosphatidylinositol phosphates modulate ATP inhibition of KATP channels by the same mechanism. J Physiol 2003; 552: 357-67.
192. [192] Shumilina E, Klöcker N, Korniychuk G, et al. Cytoplasmic accumulation of long-chain coenzyme A esters activates KATP and inhibits Kir2.1 channels. J Physiol 2006; 575: 433-42.
193. [193] Webster NJ, Searle GJ, Lam PPL, et al. Elevation in intracellular long-chain acyl-coenzyme A esters lead to reduced beta-cell excitability via activation of adenosine 5’-triphosphate-sensitive potassium channels. Endocrinology 2008; 149: 3679-87.
194. [194] Fang Y, Mohler ER, Hsieh E, et al. Hypercholesterolemia suppresses inwardly rectifying K+ channels in aortic endothelium in vitro and in vivo. Circ Res 2006; 98: 1064-71.
195. [195] Vigili de Kreutzenberg S, Puato M, Kiwanuka E, et al. Elevated non-esterified fatty acids impair nitric oxide independent vasodilation, in humans: evidence for a role of inwardly rectifying potassium channels. Atherosclerosis 2003; 169: 147-53.
196. [196] Vigili de Kreutzenberg S, Kiwanuka E, Tiengo A, et al. Visceral obesity is characterized by impaired nitric oxide-independent vasodilation. Eur Heart J 2003; 24: 1210-5.
197. [197] Mackie AR, Byron KL. Cardiovascular KCNQ (Kv7) Potassium Channels: Physiological Regulators and New Targets for Therapeutic Intervention. Mol Pharmacol 2008; 74: 1171-9.
198. [198] Fryer MW, Glover WE. Effects of 4-methyl-2-aminopyridine on [3H]-noradrenaline overflow and contractility of isolated rabbit arteries. Gen Pharmacol 1997; 29: 657-63.
199. [199] Ouyang J, Li Y, Li C, et al. Mitochondrial ROS-K+ channel signaling pathway regulated secretion of human pulmonary artery endothelial cells. Free Radic Res 2012; 46: 1437-45.
200. [200] Han WQ, Wong WT, Tian XY, et al. Contributory role of endothelium and voltage-gated potassium channels in apocynin-induced vasorelaxations. J Hypertens 2010; 28: 2102-10.
201. [201] Stafstrom CE, Grippon S, Kirkpatrick P. Ezogabine (retigabine). Nat Rev Drug Disc 2011; 10: 729-30.
202. [202] Martyn-St James M, Glanville J, McCool R, et al. The efficacy and safety of retigabine and other adjunctive treatments for refractory partial epilepsy: a systematic review and indirect comparison. Seizure 2012; 21: 665-78.
203. [203] Ferron GM, Paul J, Fruncillo R. Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers. J Clin Pharmacol 2002; 42: 175-82.
204. [204] Trobalt, INN-retigabine-CHMP assessment report. European Medicines Agency 2011. WC500104839 [1].pdf n.d.
205. [205] Main MJ, Cryan JE, Dupere JR, et al. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol Pharmacol 2000; 58: 253-62.
206. [206] Rundfeldt C, Netzer R. Investigations into the mechanism of action of the new anticonvulsant retigabine. Interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channels. Arzneimittelforschung 2000; 50: 1063-70.
207. [207] Yeung SYM, Pucovsk V, Moffatt JD, et al. Molecular expression and pharmacological identification of a role for K(v)7 channels in murine vascular reactivity. Br J Pharmacol 2007; 151: 758-70.
208. [208] Yeung S, Schwake M, Pucovsk V, et al. Bimodal effects of the Kv7 channel activator retigabine on vascular K+ currents. Br J Pharmacol 2008; 155: 62-72.
209. [209] Mackie AR, Brueggemann LI, Henderson KK, et al. Vascular KCNQ potassium channels as novel targets for the control of mesenteric artery constriction by vasopressin, based on studies in single cells, pressurized arteries, and in vivo measurements of mesenteric vascular resistance. J Pharmacol Exp Ther 2008; 325: 475-83.
210. [210] Zhong XZ, Harhun MI, Olesen SP, et al. Participation of KCNQ (Kv7) potassium channels in myogenic control of cerebral arterial diameter. J Physiol 2010; 588: 3277-93.
211. [211] Yeung SYM, Greenwood IA. Electrophysiological and functional effects of the KCNQ channel blocker XE991 on murine portal vein smooth muscle cells. Br J Pharmacol 2005; 146: 585-95.
212. [212] Joshi S, Balan P, Gurney AM. Pulmonary vasoconstrictor action of KCNQ potassium channel blockers. Respir Res 2006; 7: 31.
213. [213] Yeung SYM, Pucovsk V, Moffatt JD, et al. Molecular expression and pharmacological identification of a role for K(v)7 channels in murine vascular reactivity. Br J Pharmacol 2007; 151: 758-70.
214. [214] Fretwell L, Woolard J. Cardiovascular responses to retigabine in conscious rats-under normotensive and hypertensive conditions. Br J Pharmacol 2013; 169(6): 1279-89.
215. [215] Morecroft I, Murray A, Nilsen M, et al. Treatment with the Kv7 potassium channel activator flupirtine is beneficial in two independent mouse models of pulmonary hypertension. Br J Pharmacol 2009; 157: 1241-9.
216. [216] Jepps T A, Chadha PS, Davis AJ, et al. Downregulation of Kv7.4 channel activity in primary and secondary hypertension. Circulation 2011; 124: 602-11.
217. [217] Chadha PS, Zunke F, Zhu H-L, et al. Reduced KCNQ4-encoded voltage-dependent potassium channel activity underlies impaired-adrenoceptor-mediated relaxation of renal arteries in hypertension. Hypertension 2012; 59: 877-84.
218. [218] Löhn M, Dubrovska G, Lauterbach B, Periadventitial fat releases a vascular relaxing factor. FASEB J 2002; 16: 1057-63.
219. [219] Gao YJ, Lu C, Su LY, et al. Modulation of vascular function by perivascular adipose tissue: the role of endothelium and hydrogen peroxide. Br J Pharmacol 2007; 151: 323-31.
220. [220] Gao Y, Zeng Z, Teoh K, et al. Perivascular adipose tissue modulates vascular function in the human internal thoracic artery. J Thorac Cardiovasc Surg 2005; 130: 1130-6.
221. [221] Zavaritskaya O, Zhuravleva N, Schleifenbaum J, et al. Role of KCNQ channels in skeletal muscle arteries and periadventitial vascular dysfunction. Hypertension 2013; 61: 151-9.
222. [222] Chadha P, Zunke F, Davis A, et al. Pharmacological dissection of K(v)7.1 channels in systemic and pulmonary arteries. Br J Pharmacol 2012; 166: 1377-87.
223. [223] Yu W, Ma RC, Hu C, et al. Association between KCNQ1 genetic variants and obesity in Chinese patients with type 2 diabetes. Diabetologia 2012; 55: 2655-9.
224. [224] Chen Z, Zhang X, Ma G, et al. Association study of four variants in KCNQ1 with type 2 diabetes mellitus and premature coronary artery disease in a Chinese population. Mol Biol Rep 2010; 37: 207-12.
225. [225] Xu J, Wang P, Li Y, et al. The voltage-gated potassium channel Kv1.3 regulates peripheral insulin sensitivity. Proc Natl Acad Sci USA 2004; 101: 3112-7.
226. [226] Tucker K, Overton JM, Fadool DA. Diet-induced obesity resistance of Kv1. 3--mice is olfactory bulb dependent. J Neuroendocrinol 2012; 24: 1087-95.
227. [227] Xu J. The voltage-gated potassium channel Kv1.3 regulates energy homeostasis and body weight. Humn Mol Gen 2003; 12: 551-9.
228. [228] Straub S V, Perez SM, Tan B, et al. Pharmacological inhibition of Kv1. 3 fails to modulate insulin sensitivity in diabetic mice or human insulin-sensitive tissues. Am J Physiol Endocrinol Metab 2013; 301: E380-E390.
229. [229] Kilfoil PJ, Tipparaju SM, Barski OA, et al. Regulation of ion channels by pyridine nucleotides. Circ Res 2013; 112: 721-41.